Immuron new MTEC project proposal “Development of Oral Immunotherapy for the Prevention of Bacterial Diarrheal Disease” Key Highlights: Immuron’s request for AU$5.4M (US$4M) additional funding from the U.S. Department of Defense for Travelan considered to be ‘eligible for award’Travelan Investigational New Drug (IND)...

US Defense Reports Broad Travelan® Reactivity to 180 Pathogenic Bacteria Including Camylobacter and Shigella Key Highlights: The research program was performed by the U.S. Department of Defense (DoD) and was conducted by the Department of Enteric Diseases, Armed Forces Research Institute of Medical Sciences...